@article{ref1,
title="Effects of solriamfetol on on-the-road driving in participants with narcolepsy: a randomised crossover trial",
journal="Human psychopharmacology",
year="2022",
author="Vermeeren, Annemiek and Ramaekers, Johannes G. and Zhou, Kefei and Carter, Lawrence P. and Wang, Grace and Chen, Dan and Overeem, Sebastiaan and Lammers, Gert Jan and Vinckenbosch, Frederick",
volume="ePub",
number="ePub",
pages="ePub-ePub",
abstract="OBJECTIVE: To evaluate the impact of solriamfetol, a dopamine and norepinephrine reuptake inhibitor, on on-the-road driving performance in participants with narcolepsy. <br><br>METHODS: In this randomised, double-blind, placebo-controlled, crossover study, driving performance during a 1 h on-road driving test was assessed at 2 and 6 h post-dose following 7 days of treatment with solriamfetol (150 mg/day for 3 days, followed by 300 mg/day for 4 days) or placebo. The primary endpoint was standard deviation of lateral position (SDLP) at 2 h post-dose. <br><br>RESULTS: The study included 24 participants (54% male; mean age, 40 years); 22 had evaluable SDLP data. At 2 h post-dose, median SDLP was significantly lower (improved) with solriamfetol compared with placebo (19.08 vs. 20.46 cm [median difference, -1.9 cm], p = 0.002). Four participants on solriamfetol and 7 on placebo had incomplete driving tests. At 6 h post-dose, median SDLP was not statistically significantly different with solriamfetol compared with placebo (19.59 vs. 19.78 cm [median difference, -1.1 cm], p = 0.125). Three participants on solriamfetol and 10 on placebo had incomplete driving tests. Common adverse events (≥5%) included headache, decreased appetite, and somnolence. <br><br>CONCLUSIONS: Solriamfetol 300 mg/day improved on-the-road driving performance, at 2 h post-administration in participants with narcolepsy.<p /> <p>Language: en</p>",
language="en",
issn="0885-6222",
doi="10.1002/hup.2858",
url="http://dx.doi.org/10.1002/hup.2858"
}